A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

NCT03828747 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

272

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: Semorinemab
DRUG: Placebo
DRUG: [18F]GTP1

Sponsor

Genentech, Inc.